Elvia Cowan - 17 Mar 2026 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
SVP, Finance & CAO
Signature
Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact
Issuer symbol
PCVX
Transactions as of
17 Mar 2026
Net transactions value
-$105,147
Form type
4
Filing time
18 Mar 2026, 19:03:31 UTC
Previous filing
11 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cowan Elvia SVP, Finance & CAO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS Elvia Cowan, by /s/ Peter N. Efremenko, Attorney-In-Fact 18 Mar 2026 0001960048

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Sale $82,360 -1,487 -4.8% $55.39 29,380 17 Mar 2026 Direct F1, F2
transaction PCVX Common Stock Sale $22,787 -405 -1.4% $56.26 28,975 17 Mar 2026 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated January 29, 2026 were sold by the Reporting Person.
F2 The price reported is a weighted-average price. The shares were sold at prices ranging from $54.98 to $55.935. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. The shares were sold at prices ranging from $56.00 to $56.42. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.